research Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
Search
for
Sort by
Research
300-330 / 1000+ results
research Rizatriptan benzoate-loaded dissolving microneedle patch for management of acute migraine therapy
Rizatriptan benzoate-loaded dissolving microneedles are effective and convenient for treating acute migraines.
research Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality
5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.
research Combined drug triads for synergic neuroprotection in retinal degeneration
Using three different drugs together may better treat eye diseases like glaucoma and macular degeneration.
research Advances in the treatment of autosomal recessive congenital ichthyosis, a look towards the repositioning of drugs
Drug repositioning offers hope for new, affordable treatments for a genetic skin disorder called ARCI.
research An urticarial drug eruption caused by tofacitinib for alopecia universalis
A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
research Risk of age-related macular degeneration in men receiving 5α-reductase inhibitors: a population-based cohort study
Men taking dutasteride may have a higher risk of age-related macular degeneration.
research Captopril and alopecia: A case report and review of known cutaneous reactions in captopril use
Captopril may cause hair loss, as shown by a woman's hair regrowing after stopping the medication.
research Minoxidil in the management of intractable hypertension.
Minoxidil significantly lowers blood pressure in patients with hard-to-treat hypertension, but can cause fluid retention and excessive hair growth.
research Long-term experiences with minoxidil in combination treatment of severe arterial hypertension.
Minoxidil effectively lowers severe high blood pressure long-term but isn't for routine use.
research Anti-anginal and beta-adrenoceptor blocking drugs
Beta-blockers and anti-anginal medications have various side effects and interactions that require careful monitoring and individualized treatment.
research Severe Hypertension in Children With Renal Disease: Treatment With Minoxidil
Minoxidil lowers blood pressure in kids with kidney issues, but use carefully due to side effects.
research Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
research Bladder cancer survival in men using 5-alpha-reductase inhibitors
Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.
research Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
research MINOXIDIL-HAEMODYNAMIC AND CLINICAL EXPERIENCES WITH A NEW PERIPHERAL VASODILATOR
Minoxidil helps control blood pressure but has side-effects, so it's not for everyone.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
research Minoxidil overdose with hypotension effectively managed with norepinephrine, rather than dopamine
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research High‐dose mizoribine treatment for adolescents with systemic lupus erythematosus
High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.
research Dutasteride/finasteride
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology
Tamsulosin for enlarged prostate may increase the risk of severe low blood pressure, especially when starting or restarting the medication.
research New Drugs: Eculizumab
Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
research Drug Repurposing Patent Applications July–September 2025
New drug uses show promise but need more research.
research Dual improvement of alopecia areata and immune thrombocytopenia with baricitinib: a case report
Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
research Recalcitrant lichen planopilaris treated with upadacitinib: a case series
Upadacitinib may effectively treat resistant lichen planopilaris.
research Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
research PRIDE Complex (Papulopustules and/or Paronychia, Regulatory Abnormalities of Hair Growth, Itching, Dryness Due to EGFR Inhibitors)
PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.
research The role of 5-alpha-reductase inhibitors in active surveillance
5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.